National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 44 of 66
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
NCT00131989
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
NCT00118144
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00131911
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
NCT00217373
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00110019
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
NCT00126594
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00217399
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00138203
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT00134069
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
NCT00121199
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00126568
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
NCT00110032
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
NCT00132002
Central Nervous System Disease in HIV-infected Children on HAART
NCT00110331
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00119236
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00095979
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00112840
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
NCT00126503
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
NCT00114257
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00109967
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
NCT00113373
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
NCT00118157
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
NCT00089609
Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research
NCT00340353
Enzastaurin to Treat Recurrent Brain Tumor
NCT00108056
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00126542
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00110214
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
NCT00112736
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
NCT00108069
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
NCT00109005
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
NCT00096499
Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking
NCT00245076
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
NCT00077441
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00085254
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
NCT00124605
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCT00098488
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
NCT00103272
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00101088
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCT00098371
GW572016 to Treat Recurrent Malignant Brain Tumors
NCT00107003
Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis
NCT00340119
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00112476
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00114283
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00126490
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
NCT00126555
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
NCT00101270
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
NCT00077376
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
NCT00109811
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00121264
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00112853
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.